DEF: DarioHealth Seeks Stockholder Approval for Private Placement and Warrant Amendments

DarioHealth Corp. is seeking stockholder approval for the conversion of preferred stock, issuance of common stock, and amendments to warrants and loan agreements with Avenue Venture Opportunities Fund.

Summary

• DarioHealth Corp. is holding a special meeting of stockholders on April 28, 2025, to vote on a proposal related to a private placement and amendments to agreements with Avenue Venture Opportunities Fund.
• The proposal includes approving the conversion of 25,605 shares of Series D, D-1, D-2, and D-3 Preferred Stock into 33,956,850 shares of common stock.
• It also includes approving the issuance of up to 13,582,740 shares of common stock as dividends to the preferred stockholders.
• Additionally, the proposal seeks approval for issuing up to 4,175,070 shares of common stock as consideration under lock-up agreements with certain purchasers in the private placement who are holders of Series B and Series C Preferred Stock.
• The company is also seeking approval to reduce the exercise price of warrants held by Avenue to $0.7208 per share for 584,882 shares and to allow Avenue to convert up to $2 million of its loan at $0.8650 per share.
• The Board of Directors unanimously recommends voting FOR the Private Placement Proposal.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting factual information about proposals for stockholder vote. The tone is neutral, but the potential for improved financial flexibility through the proposed actions is a slightly positive signal.

Positives

• The Avenue Amendment extends the potential interest only period under the loan facility, provided the Company certain net proceeds from an equity financing on or before March 31, 2025 in the aggregate.
• The Avenue Amendment extends the maturity date of the loan from May 1, 2027 to November 1, 2027, provided that the Company meets the foregoing amended milestones.

Negatives

• If stockholder approval is not obtained, the preferred stock cannot be converted into common stock, and the Avenue warrants will not have their exercise price reduced.

Risks

• Failure to obtain stockholder approval could prevent the conversion of preferred stock and the repricing of warrants, potentially impacting the company's financial flexibility.
• The company's Common Stock is listed on the Nasdaq Capital Market LLC, and failure to comply with Nasdaq listing rules could result in delisting.

Future Outlook

The company has agreed to file a registration statement covering the resale of the shares of Common Stock issuable upon conversion of the Series D, D-1, D-2 D-3 Preferred Stock, thirty (30) calendar days following the receipt of shareholder approval.

Management Comments

• The Board of Directors unanimously recommends that the stockholders vote FOR the Private Placement Proposal.

Industry Context

This type of transaction is common for companies seeking to raise capital and restructure debt, especially in the healthcare technology sector. Approval of the proposals would allow DarioHealth to strengthen its financial position and potentially attract further investment.

Comparison to Industry Standards

• Repricing warrants and converting debt into equity are common strategies employed by companies in similar situations to improve their balance sheets.
• Comparable companies in the digital health space, such as Livongo (prior to its acquisition by Teladoc) and Omada Health, have also utilized private placements and warrant modifications to secure funding and manage their capital structure.
• The specific terms of the private placement and warrant amendments, such as the conversion prices and warrant exercise prices, would need to be compared to similar transactions in the industry to assess their favorability to the company and its investors.

Stakeholder Impact

• Approval of the proposals could impact shareholders by diluting existing equity.
• The outcome of the vote could affect the company's ability to raise capital and manage its debt, potentially impacting its long-term viability and employee job security.
• The proposed changes could influence the company's relationships with its lenders and investors.

Next Steps

• Stockholders need to vote on the Private Placement Proposal before the April 28, 2025 meeting.
• The company will file a Current Report on Form 8-K announcing the final voting results of the Meeting.

Key Dates